Case Report
Copyright ©The Author(s) 2018.
World J Clin Cases. Feb 16, 2018; 6(2): 11-19
Published online Feb 16, 2018. doi: 10.12998/wjcc.v6.i2.11
Table 2 Clinico-laboratory findings of herpetic hepatitis in postsurgical and non-surgical immunocompetent patients
Postsurgical patients (n = 15)Non-surgical patients (n = 42)P value
Gender (M/F) (n)8/718/240.454
Age (yr)58 (15-93) (n = 15)44 (15-87) (n = 43)0.060
Clinical manifestation
(present/absent or ND)
Fever (n)14/142/00.263
Nausea, vomiting, diarrhea (n)6/9 (17.5%)10/32 (23.8%)0.312
Herpetic lesion present/none (n)3/8 (27.3%)20/19 (51.2%)0.308
Transmission route
Identified or suspected (n)3 (20%)10 (23.8%)0.535
Surgical wounds (Trans-genital tracts) (n = 2)Sexually (n = 6)
Tran-esophagus (n = 1)Percutaneous (n = 1)
Trans-esophagus (n = 2)
Trans-rectum (n = 1)
Leukocyte count (/mm3)3905 (900-10100) (n = 14)2600 (1000-7300) (n = 39)0.152
AST (U/L)10,340 (5000-20692) (n = 10)5664 (92-18937) (n = 39)0.006
ALT5116 (2970-7000) (n = 8)3248 (141-13980) (n = 29)0.048
Total bilirubin (mg/dL)2.1 (2-8.5) (n = 6)4.4 (0.1-35) (n = 25)0.154
Serology
positive/negative (n)2/3 (40%)14/12 (53.8%)0.654
PCR analyzed (yes/no) (n)3/12 (20%)5/39 (8.4%)0.407
HSV type (1/2/1 and 2) (n)5/3/014/14/31.0
Ante-mortem diagnosis
yes/no (n)3/12 (20%)24/18 (57.1%)0.017
ACV treatment
Yes/ no (n)3/12 (20%)21 / 21 (50%)0.041
Liver transplantation
Yes/no (n)2/136/381.0
Outcome
Survived/ died (overall) (n)2/13 (13.3%)12/30 (28.6%)0.312
Survival time12 (d)13 (6-30) (n = 12)10 (5-29) (n = 26)0.729
Survival time2 after liver dysfunction emerged (d)5.5 (1-9) (n = 11)5 (1-16)) (n = 18)0.821